Benzamides and benzamidines as specific inhibitors of epidermal growth factor receptor and v-Src protein tyrosine kinases

被引:32
作者
Asano, T
Yoshikawa, T
Usui, T
Yamamoto, H
Yamamoto, Y
Uehara, Y
Nakamura, H [1 ]
机构
[1] Gakushuin Univ, Fac Sci, Dept Chem, Toshima Ku, Tokyo 1718588, Japan
[2] Tohoku Univ, Grad Sch Sci, Dept Chem, Sendai, Miyagi 9808588, Japan
[3] Natl Inst Infect Dis, Dept Bioact Mol, Tokyo 1628640, Japan
关键词
D O I
10.1016/j.bmc.2004.04.030
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The benzamides 1 and the benzamidines 2 as well as the cyclic benzamidines 3 were designed and synthesized as the mimics of 4-anilinoquinazolines for an inhibitor of EGFR tyrosine kinase. The specific inhibitions of EGFR tyrosine kinase were observed in the benzamides 1c and 1d, and the benzamidine 2a, whereas the specific inhibitions of v-Src kinase were observed in the benzamide 1j and the benzamidine 2d at a 10 mug/mL concentration of compounds. The cyclic benzamidines 3a and 3b showed potent kinase inhibition of EGFR at a 1.0 mug/mL concentration. According to the docking simulation using the X-ray structure of EGFR kinase domain in complex with erlotimb, the LigScore2 scoring function value of erlotimb was calculated as 5.61, whereas that of the benzamide 1c was 5.05. In a similar manner, the LigScore2 value of the cyclic benzamidine 3a was calculated as 5.10. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3529 / 3542
页数:14
相关论文
共 45 条
[1]   GROWTH-FACTORS AND CANCER [J].
AARONSON, SA .
SCIENCE, 1991, 254 (5035) :1146-1153
[2]   Synthesis and biological evaluation of benzamides and benzamidines: structural requirement of a pyrimidine ring for inhibition of EGFR tyrosine kinase [J].
Asano, T ;
Yoshikawa, T ;
Nakamura, H ;
Uehara, Y ;
Yamamoto, Y .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (09) :2299-2302
[3]   Design, synthesis, and biological evaluation of aminoboronic acids as growth-factor receptor inhibitors of EGFR and VEGFR-1 tyrosine kinases [J].
Asano, T ;
Nakamura, H ;
Uehara, Y ;
Yamamoto, Y .
CHEMBIOCHEM, 2004, 5 (04) :483-490
[4]   Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].
Barker, AJ ;
Gibson, KH ;
Grundy, W ;
Godfrey, AA ;
Barlow, JJ ;
Healy, MP ;
Woodburn, JR ;
Ashton, SE ;
Curry, BJ ;
Scarlett, L ;
Henthorn, L ;
Richards, L .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914
[5]  
BERTICS PJ, 1985, J BIOL CHEM, V260, P4642
[6]   Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity [J].
Boschelli, DH ;
Ye, F ;
Wang, YD ;
Dutia, M ;
Johnson, SL ;
Wu, BQ ;
Miller, K ;
Powell, DW ;
Yaczko, D ;
Young, M ;
Tischler, M ;
Arndt, K ;
Discafani, C ;
Etienne, C ;
Gibbons, J ;
Grod, J ;
Lucas, J ;
Weber, JM ;
Boschelli, F .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (23) :3965-3977
[7]   Chemical inhibitors of protein kinases [J].
Bridges, AJ .
CHEMICAL REVIEWS, 2001, 101 (08) :2541-2571
[8]   Tyrosine kinase inhibitors .8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor [J].
Bridges, AJ ;
Zhou, H ;
Cody, DR ;
Rewcastle, GW ;
McMichael, A ;
Showalter, HDH ;
Fry, DW ;
Kraker, AJ ;
Denny, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (01) :267-276
[10]   OVEREXPRESSION OF TRANSFORMING GROWTH FACTOR-ALPHA IN PSORIATIC EPIDERMIS [J].
ELDER, JT ;
FISHER, GJ ;
LINDQUIST, PB ;
BENNETT, GL ;
PITTELKOW, MR ;
COFFEY, RJ ;
ELLINGSWORTH, L ;
DERYNCK, R ;
VOORHEES, JJ .
SCIENCE, 1989, 243 (4892) :811-814